# NCT04900818 (NCT04900818)

> Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: givastomig; givastomig plus nivolumab plus chemotherapy; givastomig plus chemotherapy
- Indication: advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04900818
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: I-Mab Biopharma US Limited
- Conditions: Solid Tumor; Advanced Cancer; Metastatic Cancer; Gastric Cancer; Gastroesophageal Junction Carcinoma; Esophageal Adenocarcinoma; PDAC - Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC)
- Interventions: TJ033721 (givastomig); TJ033721 (givastomig) , nivolumab, chemotherapy; TJ033721 (givastomig), chemotherapy; TJ033721 (givastomig), durvalumab, chemotherapy
- Enrollment: 330
- Primary outcome: Dose-limiting toxicities (DLTs)
- Primary outcome: Incidence and severity of AEs
- Primary outcome: Maximum tolerated or administered dose (MTD, MAD)

## Indexed commentary on NCT04900818 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04900818
